especially with new Phase III trials for the thrombin receptor
antagonist, vicriviroc and recently in-licensed products. As a result,
Schering-Plough expects research and development expenses on a stand-
alone basis, excluding any upfront payments, to continue to grow faster
than adjusted net sales in the fourth quarter of 2007. Research and
development expenses will continue to grow in 2008. Adjusted net sales
is defined as net sales plus an assumed 50 percent of global
cholesterol joint venture net sales.
A live audio webcast of the presentation will be available by going to the Investor Relations section of the Schering-Plough corporate Web site, http://www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. A replay of the webcast will be available later that day.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.
|SOURCE Schering-Plough Corporation|
Copyright©2007 PR Newswire.
All rights reserved